Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Piccart

Showing results (131-140 of 186) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumorsF A Eskens, A Awada, D L Cutler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2019
Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trialE M Holmes, I Bradbury, L S Williams, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2002
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumoursA Awada, F A L M Eskens, M Piccart, et al.
Clinical Breast Cancer|March 20, 2002
A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923A Hamilton, D Larsimont, R Paridaens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2019
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019H J Burstein, G Curigliano, S Loibl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2018
Reply to the letter to the editor 'ESMO-MCBS v1.1: statistical and patient relevant shortcomings' by Emprechtinger et alN I Cherny, U Dafni, M Piccart, et al.
Journal of the National Cancer Institute|June 8, 2000
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized studyJ G Klijn, L V Beex, L Mauriac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2000
A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumorsE Van Den Neste, D de Valeriola, J Kerger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2014
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)F Ciardiello, D Arnold, P G Casali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 29, 2020
The legacy of Professor Aron GoldhirschR D Gelber, A S Coates, S Gelber, et al.
Pageof 19

Showing results (131-140 of 186) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumorsF A Eskens, A Awada, D L Cutler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2019
Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trialE M Holmes, I Bradbury, L S Williams, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2002
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumoursA Awada, F A L M Eskens, M Piccart, et al.
Clinical Breast Cancer|March 20, 2002
A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923A Hamilton, D Larsimont, R Paridaens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2019
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019H J Burstein, G Curigliano, S Loibl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2018
Reply to the letter to the editor 'ESMO-MCBS v1.1: statistical and patient relevant shortcomings' by Emprechtinger et alN I Cherny, U Dafni, M Piccart, et al.
Journal of the National Cancer Institute|June 8, 2000
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized studyJ G Klijn, L V Beex, L Mauriac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2000
A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumorsE Van Den Neste, D de Valeriola, J Kerger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2014
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)F Ciardiello, D Arnold, P G Casali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 29, 2020
The legacy of Professor Aron GoldhirschR D Gelber, A S Coates, S Gelber, et al.
Pageof 19